2. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014; 89:1553–1563.
3. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012; 27:1266–1280.
Article
4. Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019; 114:107–115.
Article
5. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14:542–549.
Article
6. Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol. 2017; 13:1039–1046.
Article
7. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013; 108:1268–1276.
Article
9. Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol. 2016; 29:243–248.
Article
10. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369:699–710.
Article
11. Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018; 53:1048–1064.
Article
12. Ng SC, Hilmi IN, Blake A, et al. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis. 2018; 24:2431–2441.
Article
13. Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32:769–777.
Article
14. Leung WK, Ng SC, Chow DK, et al. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013; 19:61–68.
15. Leung WK. Optimization of inflammatory bowel disease cohort studies in Asia. Intest Res. 2015; 13:208–212.
Article
16. Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017; 15:229–239.
Article
17. Colombel JF, Keir ME, Scherl A, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017; 66:2063–2068.
Article
18. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012; 18:1356–1363.
Article
19. Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019; 14:e0212989.
Article
20. Gan AT, Chan WP, Ling KL, et al. P634 Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore. J Crohns Colitis. 2019; 13(Suppl 1):S434–S435.
Article
21. Kim J, Ham NS, Oh EH, et al. P277 Real life effectiveness and safety of vedolizumab induction and maintenance therapy for Korean IBD patients in whom anti-TNF treatment failed: a prospective cohort study. J Crohns Colitis. 2019; 13(Suppl 1):S237.
Article